Tom 15, Nr 1 (2023)
Artykuł przeglądowy
Opublikowany online: 2024-05-28
Wyświetlenia strony 48
Wyświetlenia/pobrania artykułu 3
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Różnice dotyczące chorób zapalnych jelit zależne od płci

Irina Blumenstein1, Elena Sonnenberg2
DOI: 10.5603/gek.100889
Gastroenterologia Kliniczna 2023;15(1):97-110.

Streszczenie

W publikacji dokonano przeglądu aktualnych danych dotyczących różnych aspektów chorób zapalnych jelit (IBD) związanych z płcią. Główny nacisk położono na przebieg choroby, strategie leczenia farmakologicznego i chirurgicznego, różnice dotyczące uwarunkowań psychospołecznych oraz szczególne wymagania związane z ciążą i planowaniem rodziny. Najważniejsze i klinicznie istotne różnice między płciami dotyczą funkcjonowania psychospołecznego. Depresja, zmęczenie, zaburzenia lękowe, zaburzenia odżywiania i dysfunkcje seksualne w przebiegu IBD obserwuje się u obu płci, jednak wydaje się, że u kobiet występują one częściej i są bardziej nasilone.

Referencje

  1. Brahme F, Lindström C, Wenckert A. Crohn’s disease in a defined population. An epidemiological study of incidence, prevalence, mortality, and secular trends in the city of Malmö, Sweden. Gastroenterology. 1975; 69(2): 342–351.
  2. Kyle J. Crohn's disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastroenterology. 1992; 103(2): 392–399.
  3. Latour P, Louis E, Belaiche J. Incidence of inflammatory bowel disease in the area of Liège: a 3 years prospective study (1993–1996). Acta Gastro-ent Belg. 1998; 61: 410–3.
  4. Leong RWL, Lau JY, Sung JJY. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis. 2004; 10(5): 646–651.
  5. Ng SC, Bernstein C, Vatn M, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013; 62(4): 630–649.
  6. Shivananda S, Peña AS, Nap M, et al. Epidemiology of Crohn's disease in Regio Leiden, the Netherlands. A population study from 1979 to 1983. Gastroenterology. 1987; 93(5): 966–974.
  7. Wagtmans MJ, Verspaget HW, Lamers CB, et al. Gender-related differences in the clinical course of Crohn's disease. Am J Gastroenterol. 2001; 96(5): 1541–1546.
  8. Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012; 27(8): 1266–1280.
  9. Yang SK, Loftus E, Sandborn W. Epidemiology of inflammatory bowel disease in Asia. Inflammatory Bowel Dis. 2001; 7(3): 260–270.
  10. Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-Based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western countries. Gastroenterology. 2018; 155(4): 1079–1089.e3.
  11. Virta L, Auvinen A, Helenius H, et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease — a nationwide, register-based finnish case-control study. Am J Epidemiol. 2012; 175(8): 775–784.
  12. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010; 105(12): 2687–2692.
  13. Andersson RE, Olaison G, Tysk C, et al. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology. 2003; 124(1): 40–46.
  14. Lakatos PL, Vegh Z, Lovasz BD, et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis. 2013; 19(5): 1010–1017.
  15. Biedermann L, Fournier N, Misselwitz B, et al. Swiss Inflammatory Bowel Disease Cohort Study Group. High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation — data from the swiss IBD cohort study. J Crohns Colitis. 2015; 9(10): 819–829.
  16. Severs M, Spekhorst LM, Mangen MJJ, et al. Sex-related differences in patients with inflammatory bowel disease: results of 2 prospective cohort studies. Inflamm Bowel Dis. 2018; 24(6): 1298–1306.
  17. Cosnes J, Nion-Larmurier I, Afchain P, et al. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol. 2004; 2(1): 41–48.
  18. Jacenik D, Cygankiewicz AI, Mokrowiecka A, et al. Sex- and age-related estrogen signaling alteration in inflammatory bowel diseases: modulatory role of estrogen receptors. Int J Mol Sci. 2019; 20(13).
  19. Ortizo R, Lee SY, Nguyen ET, et al. Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol. 2017; 29(9): 1064–1070.
  20. Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013; 62(8): 1153–1159.
  21. Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of Crohn's disease complications in a nationwide study. Gastroenterology. 2016; 150(7): 1561–1567.e1.
  22. Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008; 103(5): 1193–1196.
  23. Zelinkova Z, Stokkers PC, van der Linde K, et al. Maternal imprinting and female predominance in familial Crohn's disease. J Crohns Colitis. 2012; 6(7): 771–776.
  24. Lin Z, Poritz L, Franke A, et al. Genetic association of nonsynonymous variants of the IL23R with familial and sporadic inflammatory bowel disease in women. Dig Dis Sci. 2010; 55(3): 739–746.
  25. Tedde A, Laura Putignano A, Bagnoli S, et al. Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner. Scand J Gastroenterol. 2008; 43(6): 712–718.
  26. Vadstrup K, Alulis S, Borsi A, et al. Extraintestinal manifestations and other comorbidities in ulcerative colitis and Crohn disease: a Danish nationwide registry study 2003–2016. Crohns Colitis 360. 2020; 2(3): otaa070.
  27. Park SK, Wong Z, Park SH, et al. Extraintestinal manifestation of inflammatory bowel disease in Asian patients: a multinational study. Dig Liver Dis. 2021; 53(2): 196–201.
  28. Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of greek patients with inflammatory bowel disease. J Crohns Colitis. 2016; 10(4): 429–436.
  29. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011; 106(1): 110–119.
  30. Algaba A, Guerra I, Ricart E, et al. Spanish GETECCU Group (ENEIDA Project). Extraintestinal manifestations in patients with inflammatory bowel disease: study based on the ENEIDA registry. Dig Dis Sci. 2021; 66(6): 2014–2023.
  31. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91(4): 854–862, doi: 10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z.
  32. Fraga M, Fournier N, Safroneeva E, et al. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol. 2017; 29(1): 91–97.
  33. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore). 1992; 71(5): 261–270.
  34. Ampuero J, Rojas‐Feria M, Castro‐Fernández M, et al. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroentero Hepatol. 2014; 29(2): 291–295.
  35. Kumar S, Pollok R, Goldsmith D. Renal and urological disorders associated with inflammatory bowel disease. Inflamm Bowel Dis. 2023; 29(8): 1306–1316.
  36. Wu Xr, Mukewar S, Kiran RP, et al. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis. 2013; 7(5): e171–e177.
  37. Sempere L, Bernabeu P, Cameo J, et al. Gender biases and diagnostic delay in inflammatory bowel disease: multicenter observational study. Inflamm Bowel Dis. 2023; 29(12): 1886–1894.
  38. Lee DW, Koo JaS, Choe JW, et al. Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol. 2017; 23(35): 6474–6481.
  39. Mazor Y, Maza I, Kaufman E, et al. Prediction of disease complication occurrence in Crohn's disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis. 2011; 5(6): 592–597.
  40. Blumenstein I, Herrmann E, Filmann N, et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis. 2011; 5(3): 203–210.
  41. Bokemeyer B, Hardt J, Hüppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis. 2013; 7(5): 355–368.
  42. Yamamoto T, Nakase H, Watanabe K, et al. iCREST-CD Study Group. Diagnosis and clinical features of perianal lesions in newly diagnosed Crohn's disease: subgroup analysis from inception cohort registry study of patients with crohn's disease (icrest-cd). J Crohns Colitis. 2023; 17(8): 1193–1206.
  43. Wada Y, Hisamatsu T, Naganuma M, et al. Risk factors for decreased bone mineral density in inflammatory bowel disease: a cross-sectional study. Clin Nutr. 2015; 34(6): 1202–1209.
  44. Walldorf J, Krummenerl A, Engler K, et al. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis. 2013; 7(11): 901–907.
  45. Bartram SA, Peaston RT, Rawlings DJ, et al. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol. 2006; 12(35): 5680–5686.
  46. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci. 1998; 43(11): 2500–2506.
  47. Haschka J, Hirschmann S, Kleyer A, et al. High-resolution quantitative computed tomography demonstrates structural defects in cortical and trabecular bone in IBD patients. J Crohns Colitis. 2016; 10(5): 532–540.
  48. Gupta S, Wu X, Moore T, et al. Frequency, risk factors, and adverse sequelae of bone loss in patients with ostomy for inflammatory bowel diseases. Inflamm Bowel Dis. 2014; 20(2): 259–264.
  49. Söderlund S, Granath F, Broström O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010; 138(5): 1697–1703.
  50. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012; 10(6): 639–645.
  51. White A, Ironmonger L, Steele RJC, et al. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer. 2018; 18(1): 906.
  52. Caso V, Paciaroni M, Agnelli G, et al. Gender differences in patients with acute ischemic stroke. Womens Health (Lond). 2010; 6(1): 51–57.
  53. Shaw LJ, Shaw RE, Merz CN, et al. American College of Cardiology-National Cardiovascular Data Registry Investigators. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation. 2008; 117(14): 1787–1801.
  54. Lesuis N, Befrits R, Nyberg F, et al. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012; 10: 82.
  55. Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther. 2009; 11(5): 252.
  56. Szalat A, Raz I. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab. 2008; 10(12): 1135–1156.
  57. Schmetzer O, Flörcken A. Sex and gender differences in pharmacology. Handb Exp Pharmacol. 2012: 411–42.
  58. Heath EM, Kim RB, Wilson A. A comparative analysis of drug therapy, disease phenotype, and health care outcomes for men and women with inflammatory bowel disease. Dig Dis Sci. 2022; 67(9): 4287–4294.
  59. Shah ED, Coburn ES, Nayyar A, et al. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2020; 51(5): 527–533.
  60. Greuter T, Manser C, Pittet V, et al. on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Gender differences in inflammatory bowel disease. Digestion. 2020; 101(Suppl 1): 98–104.
  61. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011; 106(4): 674–684.
  62. Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 2012; 6(2): 143–153.
  63. Lie MRKL, Kreijne JE, van der Woude CJ. Sex is associated with adalimumab side effects and drug survival in patients with crohn's disease. Inflamm Bowel Dis. 2017; 23(1): 75–81.
  64. Nasuno M, Miyakawa M, Tanaka H, et al. Short- and long-term outcomes of infliximab treatment for steroid-refractory ulcerative colitis and related prognostic factors: a single-center retrospective study. Digestion. 2017; 95(1): 67–71.
  65. Agrawal M, Petralia F, Tepler A, et al. Gender-Based differences in response to tumor necrosis factor inhibitor therapies for ulcerative colitis: individual participant data meta-analyses of clinical trials. Inflamm Bowel Dis. 2023; 29(1): 1–8.
  66. Zelinkova Z, Bultman E, Vogelaar L, et al. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol. 2012; 18(47): 6967–6973.
  67. Schultheiss JPD, Brand EC, Lamers E, et al. Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Aliment Pharmacol Ther. 2019; 50(4): 386–396.
  68. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis — strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008; 27(12): 1157–1166.
  69. Long MD, Kappelman MD, Martin CF, et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis. 2012; 18(11): 2099–2106.
  70. Mantzaris GJ, Roussos A, Kalantzis C, et al. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis. 2007; 13(4): 446–450.
  71. Yen L, Wu J, Hodgkins PL, et al. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012; 18(9): 701–712.
  72. Zelante A, De Giorgi A, Borgoni R, et al. Adherence to medical treatment in inflammatory bowel disease patients. Minerva Gastroenterol Dietol. 2014; 60(4): 269–274.
  73. Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013; 19(7): 1528–1533.
  74. De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther. 2015; 42(7): 867–879.
  75. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012; 107(11): 1693–1701.
  76. Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013; 19(9): 1858–1866.
  77. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012; 107(8): 1228–1235.
  78. Rottoli M, Remzi FH, Shen B, et al. Gender of the patient may influence perioperative and long-term complications after restorative proctocolectomy. Colorectal Dis. 2012; 14(3): 336–341.
  79. Wu XR, Ashburn J, Remzi FH, et al. Male gender is associated with a high risk for chronic antibiotic-refractory pouchitis and ileal pouch anastomotic sinus. J Gastrointest Surg. 2016; 20(3): 631–639.
  80. Bommena S, Goldberg A, Amini M, et al. Depression in women with inflammatory bowel disease: a multifaceted approach for a multidimensional problem. Inflamm Bowel Dis. 2023; 29(12): 1957–1970.
  81. Marafini I, Longo L, Lavasani DM, et al. High frequency of undiagnosed psychiatric disorders in inflammatory bowel diseases. J Clin Med. 2020; 9(5).
  82. Barberio B, Zamani M, Black CJ, et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021; 6(5): 359–370.
  83. Siu AL, Bibbins-Domingo K, Grossman DC, et al. US Preventive Services Task Force (USPSTF). Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016; 315(4): 380–387.
  84. Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017; 112(2): 241–258.
  85. Vigod SN, Kurdyak P, Brown HK, et al. Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut. 2019; 68(9): 1597–1605.
  86. Rivière P, Zallot C, Desobry P, et al. Frequency of and factors associated with sexual dysfunction in patients with inflammatory bowel disease. J Crohns Colitis. 2017; 11(11): 1347–1352.
  87. Beese SE, Harris IM, Moore D, et al. Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review protocol. Syst Rev. 2018; 7(1): 184.
  88. McDermott E, Mullen G, Moloney J, et al. Body image dissatisfaction. Inflammatory Bowel Diseases. 2015; 21(2): 353–360.
  89. van der Have M, van der Aalst KS, Kaptein AdA, et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis. 2014; 8(2): 93–106.
  90. Schreiner P, Rossel JB, Biedermann L, et al. Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. Aliment Pharmacol Ther. 2021; 53(1): 138–149.
  91. Bel LGJ, Vollebregt A, Jong AVd, et al. Sexual dysfunctions in men and women with inflammatory bowel disease: the influence of ibd-related clinical factors and depression on sexual function. J Sex Med. 2015; 12(7): 1557–1567.
  92. Timmer A, Bauer A, Dignass A, et al. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol. 2007; 5(1): 87–94.
  93. O'Toole A, Winter D, Friedman S. Review article: the psychosexual impact of inflammatory bowel disease in male patients. Aliment Pharmacol Ther. 2014; 39(10): 1085–1094.
  94. Feagins LA, Kane SV. Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol. 2009; 104(3): 768–773.
  95. Allocca M, Gilardi D, Fiorino G, et al. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018; 30(3): 316–322.
  96. Shin T, Okada H, Shin T, et al. Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. Syst Biol Reprod Med. 2014; 60(6): 373–376.
  97. Heetun ZS, Byrnes C, Neary P, et al. Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 26(4): 513–533.
  98. Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009; 15(5): 720–725.
  99. de Lima A, Zelinkova Z, Mulders AG, et al. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol. 2016; 14(9): 1285–1292.e1.
  100. Sands K, Jansen R, Zaslau S, et al. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther. 2015; 41(9): 821–834.
  101. Laube R, Yau Y, Selinger CP, et al. Knowledge and attitudes towards pregnancy in females with inflammatory bowel disease: an international, multi-centre study. J Crohns Colitis. 2020; 14(9): 1248–1255.
  102. Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013; 7(6): e206–e213.



Gastroenterologia Kliniczna. Postępy i Standardy